---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-275889"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:22:20.066543+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TScan Q3 net loss $35.7M; pauses solid tumor enrollment, advances heme pivotal trial

## Summary
- Revenue $2.5M (up from $1.0M YoY); net loss $35.7M vs $29.9M; cash $184.5M funds into H2 2027.
- FDA agreed on pivotal trial design for TSC-101 in AML/MDS; pivotal launch expected Q2 2026.
- Strategic decision: prioritize heme program, pause PLEXI-T solid tumor enrollment; shift to in vivo engineering.
- Plans to present updated ALLOHA heme data at ASH Dec 2025; two IND submissions for heme candidates in Q4 2025.

## SEC filing metadata
- accession: 0001193125-25-275889
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312525275889/0001193125-25-275889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312525275889/tcrx-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-275889
- JSON: https://secwatch.observer/filing/0001193125-25-275889.json
- Plain text: https://secwatch.observer/filing/0001193125-25-275889.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.